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ABSTRACT One of the most challenging problems facing
modern medicine is how to deliver a given drug to a specific
target at the exclusion of other regions. For example, a variety
of compounds have beneficial effects within the central nervous
system (CNS), but unwanted side effects in the periphery. For
such compounds, traditional oral or intravenous drug delivery
fails to provide benefit without cost. However, intranasal deliv-
ery is emerging as a noninvasive option for delivering drugs to
the CNS with minimal peripheral exposure. Additionally, this
method facilitates the delivery of large and/or charged thera-
peutics, which fail to effectively cross the blood-brain barrier
(BBB). Thus, for a variety of growth factors, hormones, neuro-
peptides and therapeutics including insulin, oxytocin, orexin,
and even stem cells, intranasal delivery is emerging as an
efficient method of administration, and represents a promising
therapeutic strategy for the treatment of diseases with CNS
involvement, such as obesity, Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease, depression, anxiety, autism spec-
trum disorders, seizures, drug addiction, eating disorders, and
stroke.
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DIRECT INTRANASAL DELIVERY TO THE CENTRAL
NERVOUS SYSTEM (CNS): TARGETING
WITH MINIMAL INVASIVENESS
Traditionally, neurological disorders, like many bodily disor-
ders, have been treated through peripheral administration
(predominantly oral administration). However, there are a
variety of issues with using peripheral administration to treat
CNS diseases. Most significantly, it is difficult to impossible for
many molecules, particularly large and/or charged ones, to
enter the brain from the bloodstream due to the blood-brain-
barrier (BBB), which keeps foreign materials out (1). Addition-
ally, first-pass metabolism can greatly reduce the bioavailabil-
ity of any drug taken orally, to the point where only a small
amount of active drug actually reaches the circulatory system
and ultimately the brain (2). Peripherally administered drugs
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can also take a significant amount of time to reach the brain,
so that in acute situations, such as seizures, patients suffer and
in some instances face other serious complications—including
an increased chance of mortality—while waiting for drug
delivery. Plasma protein binding, another consequence of
systemic administration, can also affect both the duration
and intensity of a drug’s action, reducing its ability to efficient-
ly cross the BBB (3). The final concern with systemic admin-
istration is the production of unwanted, peripherally-induced
side-effects. Compounds such as insulin, which have a variety
of desirable CNS effects, also induce dramatic systemic effects,
which can in some cases be problematic (4).
As an alternative, intracerebroventricular injection can
deliver drugs directly to the brain; however, it is highly
invasive and therefore not realistic for clinical applications
(5). On the other hand, intranasal administration, especially
to the upper portion of the nasal cavity, has been shown to
achieve direct CNS delivery of a variety of compounds
without invasiveness or major complications (6–9). In addi-
tion, it causes rapid increases in CNS levels of these com-
pounds, and for some—such as insulin—avoids any
significant peripheral uptake (10). It may thus represent
the most promising, novel, non-invasive method for deliver-
ing therapeutic substances directly to the CNS.
INTRANASAL MECHANISMS
A scheme illustrating the mechanism of nose-to-brain deliv-
ery is shown in Figure 1. While the mechanisms involved in
intranasal delivery of drugs to the brain are still being
elucidated, some of the pathways involved are known. For
example, intranasal drugs have been shown to rapidly travel
extracellularly along the olfactory nerve pathways leading
from the upper part of the nasal cavity directly to the brain
(6,9,11,12). This pathway is likely one of the largest contrib-
utors to intranasal drug delivery, as drug concentrations in
the olfactory bulbs following intranasal delivery are among
the highest in the CNS (9,13,14).
The trigeminal nerve pathways are another conduit con-
necting the nasal passages to the CNS. Unlike the olfactory
nerve, the trigeminal nerve enters the brain through both the
pons and the cribriform plate, which allows for drug delivery to
both the anterior and posterior regions of the brain (9,12).
Researchers have demonstrated that a variety of intranasally
delivered substances, including insulin-like growth factor 1
(IGF-1), interferon beta-1b and hypocretin-1 (orexin A), result
in significant levels of radioactivity in the trigeminal nerve
branches, trigeminal ganglion, and the pons, strongly suggest-
ing the involvement of trigeminal nerves in intranasal delivery
to the CNS (9,13,15). Additionally, in a recent experiment in
mice, the rostral migratory stream has been identified as an-
other potential access path for the CNS delivery of intranasally
administered agents (16). However, the relative importance of
the various pathways for CNS drug delivery remains unclear.
In general, transport of substances along the olfactory and
trigeminal nerve pathways can happen through both intracel-
lular and extracellular mechanisms (9). The intracellular
mechanisms include uptake into olfactory sensory neurons
(OSNs) within the nasal cavity via both diffusion and
Fig. 1 A scheme illustrating the
mechanism of nose-to-brain de-
livery. Unlike the olfactory nerve
which terminates in the olfactory
bulb, the trigeminal nerve enters
the brain through both the pons
and the cribriform plate, which
allows for drug delivery to both
the anterior and posterior regions
of the brain (9,12). Transport of
substances along the olfactory and
trigeminal nerve pathways can
happen through both intracellular
and extracellular mechanisms (9).
However, intracellular transport is
a slow process, requiring at best
several hours and at worst several
days (17,20). Extracellular trans-
port, on the other hand, is rapid
and likely accounts for much of
the rapid delivery and onset of
action observed with intranasal
CNS therapeutics (8,21). Abbre-
viations: ECS, extracellular space.
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endocytosis (17,18). OSNs have a demonstrated capacity to
endocytose a variety of substances, including some large mol-
ecules and viruses (19). However, intracellular transport is a
slow process, requiring at best several hours and at worst
several days (17,20). Extracellular transport, on the other
hand, is rapid and likely accounts for much of the rapid
delivery and onset of action observed with intranasal CNS
therapeutics (8,21). Within approximately 45–90 min, extra-
cellular transport delivered the tracer peroxidase to the olfac-
tory bulbs (22). Rapid intranasal delivery, as fast as 5–10 min
in some cases, of therapeutics to the CNS has been demon-
strated with a variety of intranasally delivered drugs, confirm-
ing the importance of this extracellular transport mechanism
(7,9,10,12,23–25). This rapid speed of transport suggests that
for many compounds extracellular convection—along the
olfactory and trigeminal nerves—accounts for a significant
portion of intranasal delivery to the CNS (9).
In contrast to the intranasal administration of hydrophilic
compounds, which typically results in low or no systemic
exposure while targeting the brain (10), it can be difficult to
avoid systemic exposure with an intranasally delivered small
lipophilic molecule. Using a vasoconstrictor formulation
may help reduce systemic exposure of lipophilic molecule
(26), but studies on the efficacy of this approach are lacking.
INTRANASAL INSULIN: A MULTI-PURPOSE
PHARMACOLOGICAL TOOL TO IMPROVE
CENTRAL NERVOUS SYSTEM FUNCTION
Insulin stands as perhaps the most thoroughly investigated
compound with regard to intranasal delivery for the im-
provement of CNS functioning. Intranasally administered
insulin appears to benefit a variety of measures, including
food intake, body weight, memory, and mood, while avoid-
ing many unwanted peripheral side effects. With regard to
memory, initial experiments revealed that 8 weeks of intra-
nasal insulin improves performance on a declarative
(delayed recall) memory task (27,28). Further studies have
demonstrated that intranasal insulin improves verbal mem-
ory in both cognitively impaired older adults and those with
early Alzheimer disease (AD) (29–31). In a recently pub-
lished clinical trial with 104 adults with amnestic mild cog-
nitive impairment or mild to moderate Alzheimer’s disease,
4 months of intranasal insulin administration reduced not
only general cognitive decline but also preserved metabolic
integrity of the brain, as indicated by cognitive testing and
fluorodeoxyglucose positron emission tomography (FDG-
PET) (32). These results suggest that targeting the brain
insulin pathway by means of intranasal administration of
the hormone is a promising therapeutic strategy to improve
memory and potentially deter the process of this devastating
disease (33–37). Another study demonstrated that intranasal
insulin treatment for 1 year appeared to improve the devel-
opmental delay in children suffering from 22q13 deletion
syndrome that is associated with cognitive impairments,
generalized hypotonia and autistic behavior (38). While
many of these effects have been demonstrated in both sexes,
there is some evidence suggesting that the cognitively enhanc-
ing properties of insulin are more pronounced in women than
in men (39). Additional evidence suggests that these effects are
genotype dependent, such that groups with different genetic
risk profiles for cognitive impairment or AD may show differ-
ent dose-response curves following intranasal insulin adminis-
tration. For example, memory-impaired adults with the
episolon4 allele for Apolipoprotein E (APOE)—a risk factor
for AD and impaired cognitive function—show a relative
decline in verbal memory following intranasal insulin, in con-
trast to those without this allele (29). However, the dependen-
cy on gender and genotype needs further investigation.
Intranasal insulin has also emerged as a potential treatment
for both obesity and diabetes. Eight weeks of daily adminis-
tration resulted in significant loss of body weight, fat, waist
circumference, and leptin levels in men (40). However, this
same research failed to find an effect in women, again suggest-
ing that the effects of insulin may be gender-dependent. This
conclusion is reinforced by other studies demonstrating the
same pattern of results in the acute setting, with men eating
less following intranasal insulin administration, while women
received a memory boost (39). However, there is also evidence
to the contrary. A recent study revealed that intranasal insulin
administered postprandially intensified satiety, reduced later
intake of calorie dense, palatable foods, and impacted periph-
eral glucose homeostasis in women, suggesting that intranasal
insulin may have some potential in the treatment of obesity
and diabetes in both men and women (41). Additional evi-
dence for this assumption comes from its demonstrated ability
to increase postprandial thermogenesis and energy expendi-
ture, suggesting that insulin may improve obesity and meta-
bolic syndrome not only through its anorectic properties, but
also through thermogenesis (42). Finally, functional magnetic
resonance imaging (fMRI) has revealed that intranasal insulin
selectively reduces brain activity in memory centers within the
brain, such as the hippocampus, in response to food images
(43). This could represent another mechanism by which insu-
lin suppresses rewarding food related memories, and as a
consequence food intake.
It is emerging that insulin also has stress and mood regulat-
ing properties specific to the CNS. For example, a recent study
utilizing the Tier Social Stress Test (TSST) found that intra-
nasal insulin attenuates both plasma and saliva cortisol release
in response to social challenges, demonstrating its role in reg-
ulating the hypothalamic-pituitary adrenal (HPA) axis stress
responses (44). Eight weeks of daily intranasal administration
also caused significant decreases in participants’ self-rated an-
ger and increases in their self-confidence and general well-
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being (27). However, there is still a dearth of evidence support-
ing this connection, and future studies are needed to reveal the
particular impact of central nervous insulin on the ongoing
regulation of stress reactions and emotions.
INTRANASAL LEPTIN: AN ANTI-OBESITYAGENT?
Leptin is one of the best known players in the regulation of body
weight and appetite (45). Early characterization of this anorec-
tic transmitter lead to the belief that it may serve as a magic
bullet solution to obesity. However, systemic administration of
leptin has failed to provide any substantial benefits for weight
decrease or appetite reduction in obesity (46,47). In addition,
peripheral administration of leptin fails to increase leptin con-
centrations in CSF, suggesting that the problem, at least in part,
involves the quantities of leptin able to pass the BBB (48). Based
on this reasoning, a handful of recent pre-clinical studies have
investigated the possibility that intranasal administration of
leptin may enhance its anorectic potential, and the results so
far are very positive. In trials using both lean and diet-induced
obese (DIO) rats, intranasal leptin has been demonstrated to
reduce appetite and induce weight loss (49,50). In addition,
these findings were equally substantial in the DIO and lean
groups. These experiments also found that this form of admin-
istration successfully altered the hypothalamic levels of a variety
of regulators of energy homeostasis, including neuropeptide Y,
proopiomelanocortin and agouti-related protein. Thus leptin
represents one of several compounds with apparent therapeutic
potential on the frontiers of intranasal delivery.
SOCIAL BEHAVIOR AND BODYWEIGHT: THE ROLE
OF OXYTOCIN
Oxytocin is another peptide that has been extensively inves-
tigated with intranasal administration; however, the areas of
this research are constantly expanding. Historically, intra-
nasal oxytocin has been useful for the acceleration and
augmentation of contractions during childbirth (51). How-
ever, the past decade has revealed a plethora of other
potential uses for intranasal oxytocin. Unlike insulin, oxyto-
cin does not present with many unwanted systemic effects;
however, because of the size of the molecule it is ineffective
to administer it via the periphery, as it does not seem to pass
the BBB in significant quantities (52). Thus, intranasal delivery
provides the most effective method to utilize its various ben-
eficial CNS effects. As vasopressin is known to gain access to
the CNS via intranasal administration, and oxytocin only
differs from vasopressin by two amino acids, it is reasonable
to assume that it gains access via a similar mechanism (10).
Recent research into oxytocin has largely focused on its
role in improving social behavior, and as an extension
psychiatric disorders affecting social life. Much of this re-
search was spurred by the seminal work of Kosfeld and
coworkers who revealed that oxytocin increases trust in
humans, thereby demonstrating its pro-social potential
(53). In healthy volunteers, intranasal oxytocin has also been
shown to improve performance on the Reading the Mind in
the Eyes (RMET) test, which involves detecting social cues
from the eye region (54). Follow-up research demonstrated
that this effect translates to children and adolescents (aged
12 to 19) with autism spectrum disorders, demonstrating a
clear application of oxytocin’s pro-social effects (55). Other
research has discovered that intranasal oxytocin improves
positive evaluations of appearance and speech performance
during exposure therapy for social anxiety disorder (SAD)
(56). However, this same study found no significant differ-
ence in treatment effects on SAD symptoms and dysfunc-
tional thoughts between oxytocin and placebo, so that
further research is needed to demonstrate if different dosing
regiments, or use in conjunction with alternative interven-
tions might improve oxytocin’s efficacy in SAD. Another
study demonstrated that even the highly intractable border-
line personality disorder (BPD) benefits from oxytocin—
intranasal delivery attenuated BPD stress reactivity in re-
sponse to the TSST (57). Perhaps most surprisingly, central
oxytocin also improves schizophrenia-induced social deficits
(58), including performance on the Brüne Theory of Mind
Picture Stories Task (59) and the Trustworthiness Task (60).
While oxytocin’s role in social behaviors is well established, it
may have additional therapeutic applications that have yet to
be fully explored. In rats, centrally administered oxytocin has
been shown to reduce food intake and body weight (61,62).
Recent follow up research demonstrated that this effect is
particularly pronounced in diet-induced obese rats (63). These
results suggest that centrally administered oxytocin may facili-
tate weight loss in humans, particularly in those with metabolic
syndrome, and clinical trials are currently investigating this
question (clinicaltrials.gov). There are additional reasons to
suggest that oxytocinmay be particularly effective in combating
obesity associated with Prader-Willi syndrome (PWS). PWS is a
congenital disease that produces a variety of undesirable effects,
including gross body weight gain (64). Interestingly, PWS is also
characterized by dramatically reduced levels of oxytocin in the
paraventricular nucleus of the hypothalamus—a region criti-
cally involved in body weight homeostasis (65). Thus, central
oxytocin may improve this aspect of PWS.
INTRANASAL OREXIN-A AS A THERAPEUTIC
OPTION TO TREAT NARCOLEPSY
In 2004, intranasal hypocretin-1 (orexin A) was first shown
to be delivered from the nose to the brain and proposed as a
new strategy to treat narcolepsy (16). A study in non-human
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primates demonstrated that intranasal hypocretin-1 reduces
cognitive performance deficits resulting from sleep depriva-
tion (66). However, intranasal hypocretin-1 administration is
just starting to be explored in humans. This line of research
has focused on narcolepsy—a disorder characterized by im-
paired or absent CNS hypocretin signaling—and has shown
promising results (67). Intranasal hypocretin-1 stabilizes rapid
eye movement (REM) sleep and reduces wake to REM tran-
sitions in narcoleptics when administered prior to sleep onset
(68). Olfactory dysfunction, a well-known aspect of narcolep-
sy, is also improved by intranasal hypocretin-1 (67). Animal
studies have demonstrated that intranasal administration
leads to significantly greater tissue-to-blood concentration
ratios in all brain regions over 2 h as compared to intravenous
(IV) administration. Intranasal administration also increased
drug targeting to the brain and spinal cord 5- to 8-fold (69).
While these early studies are promising, further research is
needed to assess whether the fast acting and potent intrana-
sally delivered hypocretin-1 can aid in the prevention of
cataplexy, sleep paralysis, hallucinations, excessive daytime
sleepiness, or other symptoms associated with narcolepsy.
INTRANASAL BENZODIAZEPINES: OPTIMIZING
EMERGENCY SEIZURE TREATMENT
Early intervention in a patient who is seizing reduces the
chances of both morbidity and mortality (70,71). While IV
administration is preferred, most prolonged seizures begin
outside of hospital settings. It is thus important for parents
and caretakers to have simple, cheap, and effective methods
for treating patients experiencing a seizure. Benzodiazepines,
such as diazepam, lorazepam, clonazepam andmidazolam, are
currently the most popular compounds for acutely treating
seizures (72,73). IV and intramuscular administration have
historically been standard for drug delivery in hospital settings.
Outside of the hospital, rectal treatment, which carries with it
significant social taboos—which result in delayed treatment
and sometimes decisions not to treat—is currently the preferred
method of administration (74). However, intranasal benzodia-
zepines, including midazolam and lorazepam, have been
researched extensively as possible replacement treatments, both
in and outside of the hospital, and the results have been very
promising. For example, intranasal midazolam has been shown
to be effective in 87% of patients with prolonged seizures, while
rectally delivered diazepam was only effective in 60% (75).
More recent work has found that, in 358 pediatric patients
randomly assigned one treatment or the other, there was no
detectable difference in efficacy between intranasal midazo-
lam and rectal diazepam (76). This same study and others
have reported that caregivers found the intranasal treatment
significantly easier to use, and it is also noteworthy that intra-
nasal midazolam is markedly cheaper than rectal treatments
(77). With these considerations in mind, intranasal delivery
appears to be highly effective for treatment of acute seizures,
and should be seriously considered as the preferred method of
administration both in and outside of hospital settings.
INTRANASAL NALOXONE: REVERSING OPIOID
OVERDOSE AND TREATING BINGE EATING
DISORDER
Naloxone has long been the preferred treatment for opioid
overdoses; however, parenternal administration brings with
it the risk of needlestick injury in a population that is at
higher risk for blood-borne viruses (78). Studies have thus
been investigating the possibility of intranasal administra-
tion in pre-hospital settings. One such study, utilizing 154
patients treated over 1 year by the Central California EMS
Agency, found that there was no significant difference in the
likelyhood of clinical response between intranasal (66%
response) and intravenous (56% response) administration
of naloxone (79). While this same study found that the mean
time between administration and clinical response was shorter
for IV versus intranasal delivery (8.1 vs. 12.9 min), there was no
significant difference in the average time from patient contact
to clinical response. Intranasal administration thus presents a
safe and effective alternative pre-hospital intervention for
reversing the effects of opioid overdose (80).
More recently, Lightlake Therapeutics has conducted a
6-month phase II placebo-controlled trial of intranasal nal-
oxone for the treatment of binge eating disorder with 127
subjects. Patients who received intranasal naloxone had a
highly significant reduction in the time they spent binge
eating compared to placebo. Additionally, they achieved
reduced body-mass indices (BMIs) during the second half
of the 24-week trial, and had better perceptions of their
binge eating as measured by the Binge Eating Scale (BES)
(81). Intranasal naloxone thus appears to provide benefit in
both situations involving drug overdose and binge eating.
INTRANASAL STEM CELLS AS THERAPEUTIC
OPTION FOR PARKINSON’S DISEASE,
ALZHEIMER’S DISEASE, HUNTINGTON’S
DISEASE, STROKE, AND MORE
Perhaps the most exciting recent development regarding
intranasal treatment options for CNS disorders is the dis-
covery that intranasal stem cells rapidly reach the CNS and
produce therapeutic benefit in animal models. Stem cells
have been considered for use in the treatment of a plethora
of neurological conditions, including Parkinson’s disease
(PD), AD, Huntington’s disease (HD), and stroke (82–85).
However, the BBB impairs the ability of stem cells to reach the
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CNS from the periphery, and surgery is highly invasive and
can cause a local inflammatory response that damages the
implanted stem cells, leaving noninvasive intranasal adminis-
tration as one of the most attractive therapeutic options.
Preclinical trials have already produced surprising and prom-
ising results: the first published experiments demonstrated that
intranasally administered bonemarrow-derivedmesenchymal
stem cells (MSCs) reached the brain and cerebrospinal fluid
via rapid extracellular delivery along the olfactory neural
pathway, and this delivery was significantly enhanced by
pretreatment of the nasal mucosa with hyaluronidase (86).
Following this work, efficacy of this intranasal stem cell deliv-
ery and treatment method was demonstrated in three different
animal models by three different groups of researchers.
Using a mouse model, researchers demonstrated that
28 days following cerebral hypoxia-ischemia, neonatal ani-
mals treated with intranasal MSCs had significantly im-
proved sensorimotor function in the cylinder rearing test
(87). MSCs also decreased gray and white matter loss by
34 and 37%, respectively. A second group using a unilateral
6-hydroxydopamine (6-OHDA) lesion rat model of Parkin-
son’s disease demonstrated that intranasally administered
MSCs resulted in the appearance of cells in the olfactory
bulb, cortex, hippocampus, striatum, cerebellum, brain-
stem, and spinal cord with preferential targeting of the
MSCs to the lesioned side and damaged areas of the brain
(88). Out of 1×106 MSCs applied intranasally, 24% sur-
vived for at least 4.5 months in the brains of 6-OHDA rats,
and 3% of applied MSCs were proliferative 4.5 months
after application. Intranasal stem cell treatment increased
tyrosine hydroxylase and prevented dopamine loss in the
lesioned striatum and substantia nigra and completely elim-
inated the 6-OHDA-induced increase in tunnel staining in
these brain regions. It also decreased the concentrations of
multiple proinflammatory cytokines in the lesioned side to
levels seen in the intact unleasioned side. Significant and
substantial improvement in motor function was also ob-
served following intranasal treatment with the MSCs. Thus,
intranasal administration of therapeutic stem cells provides
a promising noninvasive alternative to traumatic surgical
transplantation and allows for targeted delivery of stem cells
to the CNS with the option of chronic treatment (88).
Another research group used a similar rodent model of
Parkinson’s disease but a different intranasal delivery method
and different method (near-infrared live imaging) for detecting
cells in the brain (89). Additionally, they utilized human, as
opposed to rat stem cells, in contrast to (88). Although they
were able to detect a strong near-infrared signal in the nasal
cavity immediately, they lost the signal within 1 h. However,
this loss of signal could be explained by a variety of factors,
including the fact that human stem cells may have different
migratory capacities and paths, and may suffer from an im-
mune response in rodents. It also cannot be excluded that
near-infrared live imaging is not sensitive enough to track cell
migration into the brain after intranasal or systemic adminis-
tration, since these types of delivery imply the process of cell
migration which in turn means the appearance of single cells
distributed within certain areas in the CNS. Two reports
failed to show fluorescently labeled cells (enhanced green
fluorescent protein (EGFP) or Hoechst 33258) after intranasal
delivery of cells in rats and mice (90,91), while 4 other studies
did show successful detection of cells using Hoechst 33342
(86,92), EGFP (88) or PKH-26 labeling (a lipophilic dye that
stably integrates into the cell membrane, without disturbing its
surface marker expression) (87). Thus, the delivery efficacy
after intranasal administration should be proven either by
demonstration of CNS therapeutic effects or by various de-
tectionmethods such as detection of radiolabelled stem cells in
the brain or DNA analyses of genes (such as green fluorescent
protein, GFP) specifically expressed in the stem cells after they
reach the brain (88).
Preclinical research has also revealed that MSCs have
therapeutic potential in brains damaged by stroke. Hypoxia-
preconditioned bone marrow mesenchymal stem cells (HP-
BMSCs) delivered intranasally to mice 1 day after an ische-
mic stroke migrated to ischemic regions as early as 1 h post
delivery (91). Within 4 days, BMSCs also reduced the infarct
volume and attenuated stroke-related neurological deficits.
Additionally, 2 weeks following delivery intranasal BMSCs
significantly improved blood flow to ischemic regions. While
it has been speculated that intranasal stem cells may im-
prove other conditions that benefit from stem cell treatment,
many preclinical and clinical trials are still needed to dem-
onstrate the safety and efficacy of this approach.
CLINICAL SAFETY OF INTRANASAL
ADMINISTRATION
While there are still open questions regarding the mechanics
of intranasal administration, it is becoming increasingly
clear that this delivery route is safe and effective. A meta-
analysis of the safety, side-effects and subjective reactions to
intranasal oxytocin revealed that it produces no reliable
side-effects, and is not associated with adverse outcomes
when delivered in doses of 18–40 IU for short term use
(93). Similar reviews and meta-analyses have been published
confirming the safety of a variety of intranasal compounds,
including steroids, insulin, and midazolam (94–96). As dem-
onstrated in the above meta-analyses, intranasal administra-
tion also has a favorable side-effect profile. For instance,
although an intravenous infusion of insulin yields to in-
creased brain insulin levels (97), it has also been linked to
elevated blood pressure (98), and enhanced hypothalamo–
pituitary–adrenal secretory activity (99). In contrast, en-
hanced brain insulin for shorter time periods signaling by
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intranasal administration of the hormone has been associat-
ed with no changes in blood pressure (100) and dampened
hypothalamo–pituitary–adrenal (HPA) secretory activity
(27). This example indicates that the intranasal administra-
tion method produces less undesirable consequences while
still achieving desirable CNS results. However, while intra-
nasal delivery may, in general, produce a favorable side-
effect profile as compared to other delivery routes, each
drug must be examined for its particular effects on the nasal
mucosa, the sense of smell and the immune system as the
drug will likely enter not only the CNS but also the nasal
associated lymphatics and deep cervical lymph nodes.
CONCLUDING REMARKS
The benefits of intranasally delivered compounds contin-
ue to be discovered. With over 100 clinical trials in the
United States alone currently investigating intranasal ad-
ministration, it is a rapidly growing method of adminis-
tration (clinicaltrials.gov). The greatest promise appears
to lie in compounds such as intranasal insulin and intra-
nasal oxytocin, which are dominating the current list of
clinical trials. However, other therapeutics that are still
in pre-clinical trials, such as stem cells, also have signif-
icant therapeutic potential. The future for intranasal
delivery is thus bright, as it represents the most cutting edge
way for drugs to be quickly, easily, and non-invasively deliv-
ered directly to the CNS.
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